Characterizing the ideal antidepressant therapy to achieve remission

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 26, 2001, Pages 10-15

  Ferrier, I N ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; NEUROTRANSMITTER; NORTRIPTYLINE; PAROXETINE; SERTRALINE; VENLAFAXINE; ZIMELDINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; ELECTROCONVULSIVE THERAPY; HUMAN; META ANALYSIS; MULTICENTER STUDY; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MENTAL HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION;

EID: 0035662003     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Clinical guidelines for establishing remission in patients with depression and anxiety
2. Synergistic effects of serotonergic and noradrenergic antidepressants in combination
3. Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
4. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder
5. New standard of depression treatment: Remission and full recovery
6. Antidepressant options: Venlafaxine in perspective
7. Synaptic effects of antidepressants
8. Pharmacology of antidepressants: Characteristics of the ideal drug
9. Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression
10. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
11. Evidence of the dual mechanisms of action of venlafaxine
12. Antidepressant drug side effects
13. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors
14. Venlafaxine a new dimension in antidepressant pharmacotherapy
15. (venlafaxine hydrochloride) extended-release capsules
16. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
17. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response
18. Dose-response relationship with venlafaxine
19. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
20. Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study
21. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression
22. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
23. Differential efficacy of serotonin and norepinephrine selective antidepressants: Rationale for combined action antidepressants
24. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
25. Lessons to be learnt from meta-analyses of newer versus older antidepressants
26. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants
27. SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
28. The pharmacology of antidepressants at the synapse: Focus on newer compounds
29. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
30. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
31. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
32. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
33. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression
34. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study
35. A randomized, placebocontrolled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression